Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 27 citing articles:

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
Vishal Mathur, Ozair Alam, Nadeem Siddiqui, et al.
Molecules (2023) Vol. 28, Iss. 15, pp. 5860-5860
Open Access | Times Cited: 30
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000372-e000372
Open Access | Times Cited: 30
Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study
Hwa Yeon Ko, Sungho Bea, Dongwon Yoon, et al.
The Lancet Regional Health - Western Pacific (2025), pp. 101242-101242
Open Access | Times Cited: 1
Observational and genetic analyses clarify the relationship between type 2 diabetes mellitus and gallstone disease
Peijing Yan, Li Zhang, Chao Yang, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 6
To do one and to get more: Part I. Diabetes and bone
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022) Vol. 85, Iss. 10, pp. 965-971
Open Access | Times Cited: 21
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
Samantha B. Shapiro, Hui Yin, Oriana Hoi Yun Yu, et al.
Drug Safety (2024) Vol. 47, Iss. 8, pp. 759-769
Closed Access | Times Cited: 4
Long-term efficacy and safety of early sitagliptin initiation in individuals with type 2 diabetes: an extension of the SPIKE study
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, et al.
Diabetology International (2025)
Closed Access
Persistent effect of salt reduction in schoolchildren and their families: 1-year follow-up after an application-based cluster randomized controlled trial
Yuan Li, Puhong Zhang, Feng J. He, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
Long He, Jinwei Li, Xiong Cheng, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Global burden of gallbladder and biliary diseases (1990–2021) with healthcare workforce analysis and projections to 2035
Fuqiang Dai, Yuzhou Cai, Shuoming Yang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Abnormal blood glucose on admission and outcomes in older patients with acute calculous cholecystitis
Xu Hou, Xiaohong Jiang, Zhiheng Liu, et al.
Biomarkers in Medicine (2025), pp. 1-10
Closed Access
Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial
Abraham Edgar Gracia‐Ramos, María Pilar Cruz-Domínguez, Eduardo O. Madrigal-Santillán, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 5, pp. 108742-108742
Closed Access | Times Cited: 2
Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial
Qian Ren, Ling Li, Xiuhai Su, et al.
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?
Theocharis Koufakis, Ioanna Zografou, Michael Doumas, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 6, pp. 601-608
Closed Access | Times Cited: 5
Design, synthesis, inhibitory activity, and molecular simulations study for d-glucose-conjugated thioureas containing pyrimidine ring as multitarget inhibitors against α-amylase, α-glucosidase, DDP-4, and PTP1B in Type 2 diabetes mellitus
Vũ Ngọc Toán, Do Son Hai, Hoàng Thi Kim Van, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 10, pp. 3395-3417
Open Access | Times Cited: 1
Treatment of type 2 diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
Mee Kyoung Kim, Kyungdo Han, Hyuk‐Sang Kwon, et al.
Endocrinology and Metabolism (2023) Vol. 38, Iss. 4, pp. 426-435
Open Access | Times Cited: 3
Different genders should be considered for the extraglycemic benefits of oral antidiabetic drugs
Wen-Hsun Chang, Chia-Hao Liu
Journal of the Chinese Medical Association (2022) Vol. 85, Iss. 9, pp. 959-959
Open Access | Times Cited: 3
Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials
Meng Yu, Zheng Yang, Chongxin Chen, et al.
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System
Liyun He, Jialu Wang, Ziyi Li, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. e72-e73
Open Access | Times Cited: 3
Hypoglycemic drugs, circulating inflammatory proteins, and gallbladder diseases: A mediation mendelian randomization study
Ziqi Wang, Jinyan Zhang, Xingyao Tang, et al.
Diabetes Research and Clinical Practice (2024), pp. 111882-111882
Open Access
Pharmacophore Modeling and 3D QSAR Analysis of Pyrazole3-Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors for Type II Anti-Diabetic Therapy
Krishna Sarma Pathy
(2023) Vol. 1, Iss. 1, pp. 1-7
Open Access | Times Cited: 1
SGLT2 inhibitors improved clinical outcomes on biliary diseases beyond glycemic control in patients with type 2 diabetes
Ming Gao, Qiuyu Lin, Tingxi Zhu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top